CRISPR–Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics
BioDesign Research · 2024 · 6 · 0041
DOI: 10.34133/bdr.0041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioDesign Research, 2024. Verfasst von Guanglin Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
- ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, Zhejiang 311200, China.
- College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang 310027, China.
- Zhejiang Institute of Tianjin University, Shaoxing 312300, China.
- Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin 300072, P. R. China.
- Xianghu Laboratory, Hangzhou 311231, China.
ORCID-Profile: Yuan Yao
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Zhu, G., Zhou, X., Wen, M., Qiao, J., Li, G., & Yao, Y. (2024). CRISPR–Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics. BioDesign Research, 6, 0041. https://doi.org/10.34133/bdr.0041
Vancouver
Zhu G, Zhou X, Wen M, Qiao J, Li G, Yao Y. CRISPR–Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics. BioDesign Research. 2024;6:0041. doi:10.34133/bdr.0041
BibTeX
@article{Zhu2024,
author = {Zhu, Guanglin and Zhou, Xinzhi and Wen, Mingzhang and Qiao, Jianjun and Li, Guo and Yao, Yuan},
title = {CRISPR–Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics},
journal = {BioDesign Research},
year = {2024},
volume = {6},
pages = {0041},
doi = {10.34133/bdr.0041}
}
EUVIMED